Partners hit as Reata ends PhIII BEACON trial with bardoxolone in CKD

Abbott investors sent the company's stock down for the second day in a row after its partner Reata Pharmaceuticals said on 18 October that the private firm had terminated the Phase III BEACON clinical trial evaluating its antioxidant inflammation modulator (AIM) bardoxolone methyl (RTA 402) in the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes.